

Effective Date: Monday, January 08, 2018

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, January 08, 2018

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
54212B	Bupropion and Metabolite Confirmation (DUID/DRE), Blood (Forensic)							•	
5466B	Bupropion and Metabolite Confirmation, Blood							•	
52012B	Bupropion and Metabolite Confirmation, Blood (Forensic)							•	
5466SP	Bupropion and Metabolite Confirmation, Serum/Plasma							•	
52012SP	Bupropion and Metabolite Confirmation, Serum/Plasma (Forensic)							•	
9122B	Bupropion and Metabolite Screen, Blood							•	
9122SP	Bupropion and Metabolite Screen, Serum/Plasma							•	
0803B	Bupropion and Metabolite, Blood							•	
0803SP	Bupropion and Metabolite, Serum/Plasma							•	
54215B	Carbamazepine and Metabolite Confirmation (DUID/DRE), Blood (Forensic)				•				
54215U	Carbamazepine and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				
52015B	Carbamazepine and Metabolite Confirmation, Blood (Forensic)				•				
52015SP	Confirmation, Serum/Plasma (Forensic)				•				
52015U	Carbamazepine and Metabolite Confirmation, Urine (Forensic)				•				
0970B	Carbamazepine and Metabolite, Blood				•				
0970SP	Carbamazepine and Metabolite, Serum/Plasma				•				
0975SP	Carbamazepine-10,11-Epoxide, Serum/Plasma				•				
0975U	Carbamazepine-10,11-Epoxide, Urine				•				
2915U	Dextro / Levo Methorphan - Total, Urine				•				
54452U	Dextro / Levo Methorphan Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)				•				
52481U	Dextro / Levo Methorphan Confirmation - Total, Urine (Forensic)				•				
9205U	Dextro / Levo Methorphan Screen - Total, Urine				•				
5495U	Dextro/Levo Methorphan Confirmation - Total, Urine				•				
5495SP	Dextro/Levo Methorphan Confirmation, Serum/Plasma				•				
52451SP	Dextro/Levo Methorphan Confirmation, Serum/Plasma (Forensic)				•				



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
9205SP	Dextro/Levo Methorphan Screen, Serum/Plasma				•				
2915SP	Dextro/Levo Methorphan, Serum/Plasma				•				
2917U	Dextromethorphan and Metabolite Ratio - Total, Urine				•				
10153U	Dextrorphan / Levorphanol - Total, Urine (CSA)				•				
54349U	Dextrorphan / Levorphanol Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)				•				
5497U	Dextrorphan / Levorphanol Confirmation - Total, Urine				•				
52061U	Dextrorphan / Levorphanol Confirmation - Total, Urine (Forensic)				•				
5117SP	Dextrorphan / Levorphanol Confirmation, Serum/Plasma				•				
52061SP	Dextrorphan / Levorphanol Confirmation, Serum/Plasma (Forensic)				•				
9206U	Dextrorphan / Levorphanol Screen - Total, Urine				•				
	Dextrorphan / Levorphanol Screen, Serum/Plasma				•				
54252U	Guaifenesin Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				
52052B	Guaifenesin Confirmation, Blood (Forensic)				•				
52052SP	Guaifenesin Confirmation, Serum/Plasma (Forensic)				•				
52052U	Guaifenesin Confirmation, Urine (Forensic)				•				
2185B	Guaifenesin, Blood				•				
2185SP	Guaifenesin, Serum/Plasma				•				
2185U	Guaifenesin, Urine				•				
54259B	Lamotrigine Confirmation (DUID/DRE), Blood (Forensic)				•				
54259U	Lamotrigine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				
52059B	Lamotrigine Confirmation, Blood (Forensic)				•				
52059SP	Lamotrigine Confirmation, Serum/Plasma (Forensic)				•				
52059U	Lamotrigine Confirmation, Urine (Forensic)				•				
2484B	Lamotrigine, Blood				•				
2484SP	Lamotrigine, Serum/Plasma				•				
2484U	Lamotrigine, Urine				•				



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
55060U	Methadone Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA				•				
10038SP	Methadone and Metabolite (DUID/DRE), Serum/Plasma (Forensic) (CSA)				•				
10038U	Methadone and Metabolite (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)				•				
55047U	Methadone and Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA				•				
54005U	Methadone and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				
5682SP	Methadone and Metabolite Confirmation, Serum/Plasma				•				
50015SP	Methadone and Metabolite Confirmation, Serum/Plasma (Forensic)				•				
5682U	Methadone and Metabolite Confirmation, Urine				•				
50015U	Methadone and Metabolite Confirmation, Urine (Forensic)				•				
8722SP	Methadone and Metabolite, Serum/Plasma				•				
8722U	Methadone and Metabolite, Urine				•				
3225SP	Nuedexta®, Serum/Plasma				•				
54293B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (DUID/DRE), Blood (Forensic)				•				
52093B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)				•				
52093SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)				•				
52093U	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Urine (Forensic)				•				
3265B	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Blood				•				
3265SP	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Serum/Plasma				•				
10044SP	Phencyclidine (DUID/DRE), Serum/Plasma (Forensic) (CSA)				•	·			
10044U	Phencyclidine (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)				•				
55049U	Phencyclidine Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA) IN/LA				•				
54007U	Phencyclidine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				





Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52464SP	Phencyclidine Confirmation, Serum/Plasma				•				
5657SP	Phencyclidine Confirmation, Serum/Plasma				•				
50017SP	Phencyclidine Confirmation, Serum/Plasma (Forensic)				•				
5657U	Phencyclidine Confirmation, Urine				•				
50017U	Phencyclidine Confirmation, Urine (Forensic)				•				
52464U	Phencyclidine Confirmation, Urine (Forensic)				•				
8761SP	Phencyclidine, Serum/Plasma				•				
8761U	Phencyclidine, Urine				•				
54379B	Zonisamide Confirmation (DUID/DRE), Blood (Forensic)				•				
54379U	Zonisamide Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)				•				
52140B	Zonisamide Confirmation, Blood (Forensic)				•				
52140SP	Zonisamide Confirmation, Serum/Plasma (Forensic)				•				
52140U	Zonisamide Confirmation, Urine (Forensic)				•				
4884SP	Zonisamide, Serum/Plasma				•				



Monday, January 08, 2018

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52012B Bupropion and Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

5466B Bupropion and Metabolite Confirmation, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females)



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte. Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52012SP Bupropion and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females)



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Adults: Single 150 mg SR – 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:
		100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

5466SP Bupropion and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:
		100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

9122B	Bupropion and Metabolite Scree	n, Blood
-------	--------------------------------	----------

Scope of Analysis: LC-MS/MS (80307): Bupropion, Hydroxybupropion

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9122SP Bupropion and Metabolite Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80307): Bupropion, Hydroxybupropion

Method (CPT Code)

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:
		100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

0803B Bupropion and Metabolite, Blood

Summary of Changes: Reference Comment was changed.



Monday, January 08, 2018

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion Method (CPT Code)

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
		The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

0803SP Bupropion and Metabolite, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80338): Bupropion, Hydroxybupropion



Monday, January 08, 2018

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Bupropion	ng/mL	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL.
		Reported average bupropion peak plasma concentrations: Adults: Single 100 mg IR - 120 +/- 10 ng/mL (Males); 150 +/- 10 ng/mL (Females) Adults: Single 200 mg IR -220 +/- 20 ng/mL (Males); 270 +/- 20 ng/mL (Females) Adults: Single 150 mg SR - 140 +/- 20 ng/mL Juveniles: 100 mg/day SR for 2 weeks - 25 +/- 8 ng/mL Juveniles: 200 mg/day SR for 2 weeks - 53 +/- 22 ng/mL
		Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion	ng/mL	8 adults (Age 22-42) taking thrice daily 100 mg normal release bupropion for 2 weeks had an average peak plasma concentration of 1000 +/- 70 ng/mL hydroxybupropion.
		Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma concentrations:
		100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion

54215B Carbamazepine and Metabolite Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

54215U Carbamazepine and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic)



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52015SP Carbamazepine and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52015U Carbamazepine and Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

0970B Carbamazepine and Metabolite, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

0970SP Carbamazepine and Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

0975SP Carbamazepine-10,11-Epoxide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

0975U Carbamazepine-10,11-Epoxide, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)



Monday, January 08, 2018

Test Updates

Test Changes

2915U Dextro / Levo Methorphan - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

54452U Dextro / Levo Methorphan Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52481U Dextro / Levo Methorphan Confirmation - Total, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

9205U Dextro / Levo Methorphan Screen - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

5495U Dextro/Levo Methorphan Confirmation - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52451SP Dextro/Levo Methorphan Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

5495SP Dextro/Levo Methorphan Confirmation, Serum/Plasma



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

9205SP Dextro/Levo Methorphan Screen, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

2915SP Dextro/Levo Methorphan, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

2917U Dextromethorphan and Metabolite Ratio - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

10153U Dextrorphan / Levorphanol - Total, Urine (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

54349U Dextrorphan / Levorphanol Confirmation - Total (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52061U Dextrorphan / Levorphanol Confirmation - Total, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)



Monday, January 08, 2018

Test Updates

Test Changes

5497U Dextrorphan / Levorphanol Confirmation - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52061SP Dextrorphan / Levorphanol Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

5117SP Dextrorphan / Levorphanol Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

9206U Dextrorphan / Levorphanol Screen - Total, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2506SP Dextrorphan / Levorphanol Screen, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

54252U Guaifenesin Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52052B Guaifenesin Confirmation, Blood (Forensic)



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 1 day(s)

Refrigerated: 7 day(s) Frozen (-20 °C): 24 month(s)

52052SP Guaifenesin Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52052U Guaifenesin Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2185B Guaifenesin, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 day(s)

Refrigerated: 7 day(s)

Frozen (-20 °C): 24 month(s)

2185SP Guaifenesin, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2185U Guaifenesin, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

54259B Lamotrigine Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)



Monday, January 08, 2018

Test Updates

Test Changes

54259U Lamotrigine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52059B Lamotrigine Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52059SP Lamotrigine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52059U Lamotrigine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2484B Lamotrigine, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2484SP Lamotrigine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

2484U Lamotrigine, Urine



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

55060U Methadone Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA)

IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

10038SP Methadone and Metabolite (DUID/DRE), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

10038U Methadone and Metabolite (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

55047U Methadone and Metabolite Confirmation (Drug Impaired Driving/DRE Toxicology), Urine

(Forensic) (CSA) IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

54005U Methadone and Metabolite Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

50015SP Methadone and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)



Monday, January 08, 2018

Test Updates

Test Changes

5682SP Methadone and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

50015U Methadone and Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

5682U Methadone and Metabolite Confirmation, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

8722SP Methadone and Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 12 month(s)

8722U Methadone and Metabolite, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)

Refrigerated: 14 day(s) Frozen (-20 °C): 24 month(s)

3225SP Nuedexta®, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

54293B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation (DUID/DRE), Blood

(Forensic)



Monday, January 08, 2018

Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52093B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52093SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52093U Oxcarbazepine/Eslicarbazepine Acetate as Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

3265B Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

3265SP Oxcarbazepine/Eslicarbazepine Acetate as Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

10044SP Phencyclidine (DUID/DRE), Serum/Plasma (Forensic) (CSA)



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

10044U Phencyclidine (Qualitative) (DUID/DRE), Urine (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

55049U Phencyclidine Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic) (CSA)

IN/LA

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

54007U Phencyclidine Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

50017SP Phencyclidine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

52464SP Phencyclidine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

5657SP Phencyclidine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)



Monday, January 08, 2018

Test Updates

Test Changes

50017U Phencyclidine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

52464U Phencyclidine Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

5657U Phencyclidine Confirmation, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

8761SP Phencyclidine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

8761U Phencyclidine, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 29 day(s)

Refrigerated: 29 day(s) Frozen (-20 °C): 24 month(s)

54379B Zonisamide Confirmation (DUID/DRE), Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

54379U Zonisamide Confirmation (Qualitative) (DUID/DRE), Urine (Forensic)



Monday, January 08, 2018

Test Updates

Test Changes

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52140B Zonisamide Confirmation, Blood (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52140SP Zonisamide Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

52140U Zonisamide Confirmation, Urine (Forensic)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)

4884SP Zonisamide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)

Refrigerated: 30 day(s) Frozen (-20 °C): 24 month(s)